- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statement of Provectus Biopharmaceuticals, Inc. (the “Company”) on Form S-3 (File No. 333-205704) of our report, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, dated March 31, 2017, with respect to our audit of the consolidated financial statements of Provectus Biopharmaceuticals, Inc. as of December 31, 2016 and for the year then ended and our report dated March 31, 2017 with respect to our audit of the effectiveness of internal control over financial reporting of Provectus Biopharmaceuticals, Inc. as of December 31, 2016, which reports are included in this Annual Report on Form 10-K of Provectus Biopharmaceuticals, Inc. for the year ended December 31, 2016.
Our report on the effectiveness of internal control over financial reporting expressed an adverse opinion because of the existence of material weaknesses.
/s/ Marcum LLP
Marcum LLP
New York, NY
March 31, 2017